Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.61 is 105% below its 5-year average of -0.30, near the low end of its 5-year range (-0.61–-0.25).
75.70% below its 12-month average of -0.35.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.23.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 28 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.61
EARNINGS PER SHARE (EPS) AVG TTM
-0.35
EARNINGS PER SHARE (EPS) AVG 3Y
-0.32
EARNINGS PER SHARE (EPS) AVG 5Y
-0.30
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-75.70%
CURRENT VS 3Y AVG
-93.46%
CURRENT VS 5Y AVG
-104.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NervGen Pharma Corp. Common stock
Market Cap
$147.54M
Earnings Per Share (EPS)
-0.61
TTM Avg
-0.35
3Y Avg
-0.32
5Y Avg
-0.30
Market Cap
$147.97M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.38
3Y Avg
-0.76
5Y Avg
-1.59
Market Cap
$147.49M
Earnings Per Share (EPS)
-12.04
TTM Avg
-8.05
3Y Avg
-55.02
5Y Avg
-123.25
Market Cap
$146.30M
Earnings Per Share (EPS)
-1.04
TTM Avg
-1.66
3Y Avg
-1.77
5Y Avg
-1.60
Market Cap
$150.59M
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.85
3Y Avg
-1.46
5Y Avg
-1.46
Market Cap
$152.45M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.53
3Y Avg
-0.57
5Y Avg
-0.55
Market Cap
$152.26M
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.70
3Y Avg
-0.76
5Y Avg
-0.63
Market Cap
$143.10M
Earnings Per Share (EPS)
-2.52
TTM Avg
-2.32
3Y Avg
-1.91
5Y Avg
-1.63
Market Cap
$154.46M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.32
3Y Avg
-0.33
5Y Avg
-0.37
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $147.54M | -0.61 | -0.35 | -0.32 | -0.30 |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | -0.51 | -0.38 | -0.76 | -1.59 |
| Korsana Biosciences, Inc. (KRSA)vs › | $147.49M | -12.04 | -8.05 | -55.02 | -123.25 |
| Immuneering Corporation (IMRX)vs › | $146.30M | -1.04 | -1.66 | -1.77 | -1.60 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $150.59M | -1.64 | -1.85 | -1.46 | -1.46 |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -0.26 | -0.53 | -0.57 | -0.55 |
| Codexis, Inc. (CDXS)vs › | $152.26M | -0.34 | -0.70 | -0.76 | -0.63 |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -2.52 | -2.32 | -1.91 | -1.63 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $154.46M | -0.26 | -0.32 | -0.33 | -0.37 |
| AirSculpt Technologies, Inc. (AIRS)vs › | $142.15M | -0.18 | -0.17 | -0.17 | -0.09 |
Trailing EPS (TTM)
$-0.61
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.44 |
| 2024-12-31 | -0.25 |
| 2023-12-31 | -0.28 |
| 2022-12-31 | -0.29 |
| 2021-12-31 | -0.26 |
| 2020-12-31 | -0.27 |
| 2019-12-31 | -0.30 |
| 2018-12-31 | -0.04 |
| 2017-12-31 | 0.00 |
